Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGFR + nab-paclitaxel + capecitabine
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of a vascular endothelial growth factor receptor (VEGFR) inhibitor, nab-paclitaxel (nanoparticle albumin-bound paclitaxel), and capecitabine. VEGFR inhibitors are targeted therapies that block the activity of the VEGF/VEGFR pathway, thereby inhibiting angiogenesis—the formation of new blood vessels—which is critical for tumor growth and metastasis[6][2][4]. Nab-paclitaxel is a microtubule inhibitor formulated as albumin-bound nanoparticles to enhance delivery and reduce toxicity compared to conventional paclitaxel. Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body, interfering with DNA synthesis in rapidly dividing cells. This combination aims to target tumor vasculature, disrupt cell division, and inhibit DNA synthesis for synergistic antitumor effects.
- Other names
- VEGFR inhibitor + nab-paclitaxel + capecitabineapatinib + nab-paclitaxel + capecitabineVEGFR + nab-paclitaxel + capecitabine
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on VEGFR + nab-paclitaxel + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGFR + nab-paclitaxel + capecitabine.